  Purpose: To evaluate the clinical need for automated decision-support
platforms for Adaptive Radiotherapy Therapy (ART) of Head & Neck cancer (HNC)
patients. Methods: We tested RTapp (SegAna), a new decision-support software
for ART, to investigate 22 HNC patients data retrospectively. For each
fraction, RTapp estimated the daily and cumulative doses received by targets
and OARs from daily 3D imaging in real-time. RTapp also included a prediction
algorithm that analyzed dosimetric parameters (DP) trends against dosimetric
endpoints (DE) to trigger adaptation up to 4 fractions ahead. Warning (V95<95%)
and adaptation (V95<93%) DEs were set for PTVs. OAR adaptation DEs of +10%
(DE10) were set for all Dmax and Dmean DPs. Any DE violation at end of
treatment (EOT) triggered a DP trends review to determine the DE-crossing
fraction Fx and evaluate the prediction model accuracy (difference between
calculated and predicted DP values with 95% confidence intervals). Results:
RTapp was able to address the needs of treatment adaptation. 15/22 studies
(68%) violated PTV coverage or parotids Dmean at EOT. 9 PTVs had V95<95% (mean
coverage decrease of -7.7+/-3.3 %) including 4 flagged for adaptation at median
Fx=11.5 (range: 6-18). 15 parotids were flagged for exceeding Dmean constraints
with median increase of +3.18 Gy (range: 0.18-6.31 Gy) at EOT, including 8 with
DP>DE10. The differences between predicted and calculated PTV V95 and parotids
Dmean was up to 7.6% (mean: -2.9+/-4.6 %) and 5 Gy (mean: 0.2+/-1.6 Gy),
respectively. The most accurate predictions were obtained closest to Fx. For
parotids, Fx ranged between fractions 1 to 23, the lack of specific trend
demonstrated the need to verify treatment adaptation for every fraction.
Conclusion: Integrated in an ART clinical workflow, RTapp can predict whether
specific treatment would require adaptation up to 4 fractions ahead of time.
